Gefitinib in Non Small Cell Lung Cancer

Gefitinib is an oral, reversible, tyrosine kinase inhibitor of epidermal growth factor receptor (EGFR) that plays a key role in the biology of non small cell lung cancer (NSCLC). Phase I studies indicated that the recommended dose of gefitinib was 250 mg/day. Rash, diarrhea, and nausea were the most...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Costanzo, Raffaele, Piccirillo, Maria Carmela, Sandomenico, Claudia, Carillio, Guido, Montanino, Agnese, Daniele, Gennaro, Giordano, Pasqualina, Bryce, Jane, De Feo, Gianfranco, Di Maio, Massimo, Rocco, Gaetano, Normanno, Nicola, Perrone, Francesco, Morabito, Alessandro
Format: Artigo
Sprache:Inglês
Veröffentlicht: Hindawi Publishing Corporation 2011
Schlagworte:
Review Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC3110340/
https://ncbi.nlm.nih.gov/pubmed/21660144
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2011/815269
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge